Rilvegostomig
- Generic Name
- Rilvegostomig
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- 🇹🇭
Research Site, Hat Yai, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath